Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival : on behalf of the ALWP of the EBMT and the MSKCC

Show full item record



Permalink

http://hdl.handle.net/10138/258654

Citation

Malard , F , Labopin , M , Cho , C , Blaise , D , Papadopoulos , E B , Passweg , J , O'Reilly , R , Forcade , E , Maloy , M , Volin , L , Castro-Malaspina , H , Hicheri , Y , Jakubowski , A A , Orvain , C , Giralt , S , Mohty , M , Nagler , A & Perales , M-A 2018 , ' Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival : on behalf of the ALWP of the EBMT and the MSKCC ' , Journal of Hematology & Oncology , vol. 11 , 127 . https://doi.org/10.1186/s13045-018-0668-3

Title: Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival : on behalf of the ALWP of the EBMT and the MSKCC
Author: Malard, Florent; Labopin, Myriam; Cho, Christina; Blaise, Didier; Papadopoulos, Esperanza B.; Passweg, Jakob; O'Reilly, Richard; Forcade, Edouard; Maloy, Molly; Volin, Liisa; Castro-Malaspina, Hugo; Hicheri, Yosr; Jakubowski, Ann A.; Orvain, Corentin; Giralt, Sergio; Mohty, Mohamad; Nagler, Arnon; Perales, Miguel-Angel
Contributor: University of Helsinki, Clinicum
Date: 2018-10-20
Language: eng
Number of pages: 11
Belongs to series: Journal of Hematology & Oncology
ISSN: 1756-8722
URI: http://hdl.handle.net/10138/258654
Abstract: BackgroundGraft-versus-host disease (GVHD) is one of the leading causes of non-relapse mortality and morbidity after allogeneic hematopoietic stem cell transplantation (allo-HCT).MethodsWe evaluated the outcomes of two well-established strategies used for GVHD prevention: in vivo T cell depletion using antithymocyte globulin (ATG) and ex vivo T cell depletion using a CD34-selected (CD34+) graft. A total of 525 adult patients (363 ATG, 162 CD34+) with intermediate or high-risk cytogenetics acute myeloid leukemia (AML) in first complete remission (CR1) were included. Patients underwent myeloablative allo-HCT using matched related or unrelated donors.ResultsTwo-year overall survival estimate was 69.9% (95% CI, 58.5-69.4) in the ATG group and 67.6% (95% CI, 60.3-74.9) in the CD34+ group (p=0.31). The cumulative incidence of grade II-IV acute GVHD and chronic GVHD was higher in the ATG cohort [HR 2.0 (95% CI 1.1-3.7), p=0.02; HR 15.1 (95% CI 5.3-42.2), p
Subject: Acute myeloid leukemia
T cell depletion
CD34-selected graft
Antithymocyte globulin
Allogeneic hematopoietic cell transplantation
VERSUS-HOST-DISEASE
ACUTE MYELOGENOUS LEUKEMIA
ANTI-THYMOCYTE GLOBULIN
CHRONIC GRAFT
UNRELATED DONOR
HEMATOLOGIC MALIGNANCIES
ANTITHYMOCYTE GLOBULIN
CLINICAL-TRIALS
BONE-MARROW
OPEN-LABEL
3122 Cancers
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
s13045_018_0668_3.pdf 732.2Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record